Effect of Quinapril on In-Stent Restenosis and Relation to Plasma Apoptosis Signaling Molecules

American Journal of Cardiology

Volumn 105, Issue 1, 2010, Pages 54-58

  Deftereos, Spyridon ^a   Giannopoulos, Georgios ^a   Kossyvakis, Charalampos ^a   Kaoukis, Andreas ^a   Raisakis, Konstantin ^a   Driva, Metaxia ^a   Panagopoulou, Vasiliki ^a   Lappos, Spyridon ^a   Rentoukas, Ilias ^b   Pyrgakis, Vlasios ^a   Alpert, Martin A ^c  

^a IASO GENERAL HOSPITAL   (Greece)

^b A Fleming General Hospital   (Greece)

^c University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; PLACEBO; QUINAPRIL;

ADULT; AGED; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; DRUG INHIBITION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESTENOSIS; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; SIGNAL TRANSDUCTION; STENTS; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME;

EID: 72049097123     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.08.648     Document Type: Article

References (18)

1. Hoffman R., Mintz G.S., Dussaillant G.R., Popma J.J., Pichard A.D., Satler L.F., Kent K.M., Griffin J., and Leon M. Patterns and mechanisms of in-stent restenosis: a serial intravascular ultrasound study. Circulation 94 (1996) 1247-1254
2. Cai W., Devaux B., Schaper W., and Schaper J. The role of Fas/APO-1 and apoptosis in the development of human atherosclerotic lesions. Atherosclerosis 131 (1997) 177-186
3. Jiang C., Yang Y.F., and Cheng S.H. Fas ligand gene therapy for vascular intimal hyperplasia. Curr Gene Ther 4 (2004) 33-39
4. Holm A.M., Andersen C.B., Haunso S., and Hansen P.R. ACE-inhibition promotes apoptosis after balloon injury of rat carotid arteries. Cardivasc Res 45 (2000) 777-782
5. Nagata S., and Golstein P. The Fas death factor. Science 267 (1995) 1449-1456
6. Cleveland J.L., and Ihle J.N. Contenders in FasL/TNF death signaling. Cell 81 (1995) 479-482
7. Okura T., Watanabe S., Jiang Y., Nakamura M., Takata Y., Yang Z., Kohara K., Kitami Y., and Hiwada K. Soluble Fas ligand and atherosclerosis in hypertensive patients. J Hypertens 20 (2002) 895-898
8. Adamopoulos S., Parissis J., and Kremastinos D. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail 3 (2001) 517-526
9. Mnjoyan Z.H., Doan D., Brandon J.L., Sitter C.L., Rege A.A., Brock T.A., and Fujise K. The critical role of intrinsic VSMC proliferation and death programs in injury-induced neointimal hyperplasia. Am J Physiol 294 (2008) H2276-H2284
10. Powell J.S., Clozel J.P., Muller R.K., Kuhn H., Hefti F., Hosang M., and Baumgartner H.R. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245 (1989) 186-188
11. Ellis S.G., Lincoff A.M., Whitlow P.L., Raymond R.E., Franco I., Schneider J.P., and Topol E.J. Evidence that angiotensin-converting enzyme inhibitor use diminishes the need for coronary revascularization after stenting. Am J Cardiol 89 (2002) 937-490
12. Kondo J., Sone T., Tsuboi H., Mukawa H., Kosokabe T., Tsuzuki M., Tomida T., Suzuki T., Kamiya H., Hayashi K., Matsui H., and Okumura K. Effect of quinapril on intimal hyperplasia after coronary stenting as assessed by intravascular ultrasound. Am J Cardiol 87 (2001) 443-445
13. Okumura K., Sone T., Kondo J., Tsuboi H., Mukawa H., Tsuzuki M., Imai H., Kamiya H., Mabuchi Y., Matsui H., and Hayakawa T. Quinapril prevents restenosis after coronary stenting in patients with angiotensin-converting enzyme D allele. Circ J 66 (2002) 311-316
14. Maurice T., Bauters C., Hermant X., Codron V., VanBelle E., McFadden E., Lablanche J., Bertrand M., and Amouyel P. Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomized, double-blind, placebo controlled trial. Lancet 357 (2001) 1321-1324
15. Jorgensen E., Kelbaek H., Helqvist S., Jensen G.V.H., Saunamaki K., Kastrup J., Havndrup O., Bundgaard H., Madsen J.K., Christiansen M., Andersen P.S., and Reiber J.H.C. Predictors of coronary in-stent restenosis: importance of angiotensin-converting enzyme gene polymorphism and treatment with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 38 (2001) 1434-1439
16. Cashin-Hemphill L., Holmvang G., Chan R.C., Pitt B., Dinsmore R.E., Lees R.S., and QUIET Investigators. Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. Am J Cardiol 83 (1999) 43-47
17. Peters S., Gotting B., Trammel M., Rust H., and Brattstrom A. Valsartan for Prevention of Restenosis After Stenting of Type B2/C Lesions: the VAL-PREST trial. J Invas Cardiol 13 (2001) 93-97
18. deBois D., Tea B.S., Dam T.V., Tremblay J., and Hamet P. Smooth muscle apoptosis during vascular regression in spontaneously hypertensive rats. Hypertension 29 (1997) 340-349